K-PHOS ORIGINAL Rx
Generic Name and Formulations:
Potassium acid phosphate 500mg; equiv. to potassium 3.67mEq; scored tabs.
Indications for K-PHOS ORIGINAL:
2 tabs dissolved in 6–8oz water 4 times a day with meals and at bedtime.
Renal or adrenal insufficiency. Severe hepatic disease. Infected phosphate stones. Hyperphosphatemia. Hyperkalemia (Original).
Electrolyte restrictions. Cardiac disease. Hypertension. Edema. Monitor serum electrolytes and for GI obstruction. Discontinue if laxation persists after dosage reduction. Hypoparathyroidism. Osteomalacia. Pancreatitis. Dehydration. Toxemia of pregnancy. Pregnancy (Cat.C). Nursing mothers.
Antagonized by antacids. Hyperkalemia with ACE inhibitors, triamterene, spironolactone, amiloride, potassium supplements. Toxicity with digitalis. Hypernatremia with methyldopa, guanethidine, other antihypertensives, corticotropins, mineralocorticoids.
Small bowel lesions, laxation, headache, dizziness, hyperacidity, nausea, weakness, confusion, paresthesias, seizures, arrhythmias, shortness of breath, edema.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies